Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Baas

Showing results (141-150 of 159) with videos related to

Pageof 16
Sort By:
BMC Psychiatry|February 15, 2019
Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trialFebe E van der Flier, Caroline M B Kwee, Danielle C Cath, et al.
British Journal of Cancer|March 5, 2002
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesotheliomaJ M W van Haarst, P Baas, Ch Manegold, et al.
ESMO Real World Data and Digital Oncology|April 20, 2026
Optimisation and validation of line-of-therapy advancement algorithms in advanced/metastatic non-small-cell lung cancer: an I-O Optimise studyS Lay-Flurrie, A Greystoke, C Rault, et al.
Immuno-Oncology Technology|August 4, 2025
Properties of CD8 T-cell-recognized neoantigens in different tumor typesS L C Ketelaars, M M van Buuren, A Gangaev, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2013
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)H J M Groen, M A Socinski, F Grossi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2016
Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysisD De Ruysscher, B Lueza, C Le Péchoux, et al.
The European Respiratory Journal|September 1, 2009
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesotheliomaA Scherpereel, P Astoul, P Baas, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 1998
Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative GroupT Sahmoud, P E Postmus, C van Pottelsberghe, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 28, 2010
[Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma]A Scherpereel, P Astoul, P Baas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 6, 2022
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743S Peters, A Scherpereel, R Cornelissen, et al.
Pageof 16

Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
BMC Psychiatry|February 15, 2019
Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trialFebe E van der Flier, Caroline M B Kwee, Danielle C Cath, et al.
British Journal of Cancer|March 5, 2002
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesotheliomaJ M W van Haarst, P Baas, Ch Manegold, et al.
ESMO Real World Data and Digital Oncology|April 20, 2026
Optimisation and validation of line-of-therapy advancement algorithms in advanced/metastatic non-small-cell lung cancer: an I-O Optimise studyS Lay-Flurrie, A Greystoke, C Rault, et al.
Immuno-Oncology Technology|August 4, 2025
Properties of CD8 T-cell-recognized neoantigens in different tumor typesS L C Ketelaars, M M van Buuren, A Gangaev, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2013
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)H J M Groen, M A Socinski, F Grossi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2016
Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysisD De Ruysscher, B Lueza, C Le Péchoux, et al.
The European Respiratory Journal|September 1, 2009
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesotheliomaA Scherpereel, P Astoul, P Baas, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 1998
Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative GroupT Sahmoud, P E Postmus, C van Pottelsberghe, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 28, 2010
[Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma]A Scherpereel, P Astoul, P Baas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 6, 2022
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743S Peters, A Scherpereel, R Cornelissen, et al.
Pageof 16